For the first time, the landmark study of anti-inflammatory therapy for AS, the Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS), demonstrated that anti-inflammatory drugs targeting IL-1β (such as canakinumab) can reduce the incidence of adverse cardiovascular events in patients with MI by lowering lipid levels (108). The gene discussed is IL1B; the disease is aortic stenosis.